Yue Wang - research works

We propose MoESurv, a zero-sample survival prediction framework that leverages a mix-ture-of-experts architecture to extract generalizable prognostic patterns from pan-cancer data.

The model integrates shared experts, cancer-specific experts, and routing experts within an autoencoder to disentangle common and type-specific survival features.

Further-more, external validation across diverse populations and independent cohorts-including a Chinese glioma cohort (CGGA mRNAseq_693, C-index=0.7433), a rare GBM IDH-mutant subtype (C-index=0.8064), and the pan-cancer PCAWG cohort (C-index=0.7090)-demonstrated that MoESurv possesses the most robust predictive per-formance, highlighting its generalizability.

Thirty-three point nine percent of patients developed PSD.

RCS analysis suggested a potential non-linear relationship, and a two-piecewise logistic regression model identified a candidate inflection point.

However, the wide confidence intervals in the higher exposure range indicate substantial uncertainty, and this finding should be regarded as exploratory.

The median age of onset was 2.09 years, and 60.7% of patients were aged under 3 years.

Unilateral facial and/or perioral twitching occurred in 33.9% of patients, all of whom under 5 years of age, with the highest incidence in the preschool group (70.0%, p = 0.001).

The incidence of post-encephalitic epilepsy (PE) was 53.6%, of which 63.3% were drug-refractory.

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis developed in 17.9% of patients, and its incidence increased significantly with age ( p = 0.002).

Among the 39,940 participants (weighted average age: 46.84; 50.86% female), the age-standardized prevalence of multimorbidity rose significantly, from 15.87% (95% confidence interval [CI] = 14.86%-16.87%) in 1999 to 2000 to 19.96% (95% CI = 17.61%-22.32%) in 2017 to 2018.

The population's multimorbidity detection rate was 25.22%.

The all-cause mortality risks for multimorbidity were: dual-multimorbidity (hazard ratio [HR] = 1.97, 95% CI = 1.76-2.20), triple-multimorbidity (HR = 2.69, 95% CI = 2.35-3.08), quadruple-multimorbidity (HR = 3.22, 95% CI = 2.59-3.99). "Diabetes mellitus + cardiovascular disease + respiratory diseases" had the highest mortality risk (HR = 4.37, 95% CI = 2.67-7.16).

Both PIED and UBED groups demonstrated significant postoperative improvements in lumbar and leg pain VAS scores and ODI scores ( P < 0.001).

Additionally, the PIED group had lower lumbar pain VAS scores at final follow-up (0.6 ± 0.6 vs 1.2 ± 0.9, P < 0.05).

No postoperative drainage was required in the PIED group, while the UBED group required a mean drain duration of 2.7 ± 0.7 days with a mean output of 71.6 ± 38.3 mL.

No significant differences were observed in final ODI scores or overall clinical outcomes based on the modified MacNab criteria (96.6% vs 86.2%, P = 0.297).

CCDC22 exhibits distinct spatiotemporal expression dynamics and chromatin accessibility patterns closely associated with neurodevelopmental processes.

PPI and functional enrichment analyses highlighted its core involvement in endocytic recycling and vesicle transport.

ClinPred, M-CAP, and MetaRNN achieved the highest AUC value (> 0.9).

The overall incidence of perioperative adverse events was lower in the ciprofol group (28.3% vs 64.6%, P < 0.001).

Injection pain was observed in 34.5% of patients receiving propofol and in none receiving ciprofol.

PONV, hemodynamic instability, procedure time, time to discharge, post-procedure pain scores and patient satisfaction were comparable between groups.

No serious adverse events occurred.

Of the 162 enrolled patients with suspected UA, 89 (54.9%) were diagnosed with OCAD.

Six predictors were incorporated into the diagnostic model, including hyperlipidemia, diabetes, typical angina pectoris, 18 F-FDG PET results, serum creatinine, and left ventricular ejection fraction (LVEF).

The Hosmer-Lemeshow goodness-of-fit test revealed good model fit (χ 2 =6.15, P=0.63).

After internal validation via the bootstrap method, the optimism-corrected AUC was 0.87 (95% CI: 0.82-0.93).

Complication rates were comparable between groups (p > 0.05).

Current management of coGVHD faces challenges, with frequent missed or misdiagnosed cases.

In external validation, the early warning AUROC was 83.45%, while diagnostic AUROCs across three external sites were all above 96.0%.

Gram-negative 75.4% (270,609), Gram-positive 24.6% (88,177) of 358,786 isolates from cancer patients in these oncology centers.

Klebsiella pneumoniae showed stable imipenem resistance (1.6-1.9%) but increasing meropenem resistance (0.4-1.6%).

Pseudomonas aeruginosa imipenem resistance declined (12.5-7.9%), while meropenem resistance remained stable (7.0-5.2%); while Acinetobacter baumannii carbapenem resistance increased substantially (imipenem: 9.6-18.4%; meropenem: 4.7-18.8%).